‘Supercharger’ to revive mainstay antibiotic in global fight against antibiotic resistance.
Revolutionary new treatment that involves the revitalisation of a well-known antibiotic to enter clinical trials in Australia this year.
Positive efficacy of STM-001 has again been demonstrated in our third in vivo study using an established UTI model, with a leading American research institute. This instils great confidence as we move our lead compound forward to the final stages of preclinical development.
STM’s latest manuscript, entitled "In vivo targeting of E. coli with vancomycin-arginine" has been accepted for publication in Antimicrobial Agents and Chemotherapy. What a great way to end a productive year!
We are pleased to announce that we have recently concluded a comprehensive Maximal Tolerated Dose (MTD) study of our lead compound STM-001 in rats. The study was carried out by an established American company and demonstrated tolerability well above the intended dose range, allowing for a large therapeutic window.
STM has just reached a major proof-of-concept milestone in the completion of a challenging thigh muscle in vivo study (supported by a premier UK-based CRO), in which STM-001 reduced E. coli bacterial burden by 7 log10, superseding the current standard of care (ciprofloxacin)
Retention of antibacterial activity against all ESBL, carbapenem- and colistin resistant E. coli strains has been verified in minimum inhibitory concentration (MIC) testing of STM-001.